Fibromyalgia syndrome: The role of neurochemicals

Primary Psychiatry

Volumn 13, Issue 9, 2006, Pages 72-75

  Spaeth, Michael ^a,b  

^a Center for Clinical Rheumatology Research   (Germany)

^b Rheumatologische Schwerpunktpraxis   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NERVE GROWTH FACTOR; NEUROKININ 1 RECEPTOR; NEUROPEPTIDE; NORADRENALIN; SEROTONIN; SEROTONIN 3 RECEPTOR; SUBSTANCE P;

CENTRAL NERVOUS SYSTEM; FIBROMYALGIA; HUMAN; NEUROTRANSMISSION; NOCICEPTION; PAIN; REVIEW; SENSITIZATION; SLEEP WAKING CYCLE; SYNDROME DELINEATION;

EID: 33748950664     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Bengtsson A, Henriksson KG, Larsson J. Muscle biopsy in primary fibromyalgia. Light-microscopical and histochemical findings. Scand J Rheumatol. 1986;15(1):1-6.
2. Drewes AM, Andreasen A, Schroder HD, Hogsaa B, Jennum P. Pathology of skeletal muscle in fibromyalgia: a histo-immuno-chemical and ultrastructural study. Br J Rheumatol. 1993;32(6):479-483.
3. Fassbender HG, Wegner K. Morphology and pathogenesis of soft-tissue rheumatism [German]. Z Rheumaforsch. 1973;32(9):355-374.
4. Kalyan Raman UP, Kalyan Raman K, Yunus MB, Masi AT. Muscle pathology in primary fibromyalgia syndrome: a light microscopic, histochemical and ultrastructural study. J Rheumatol. 1984;11(6):808-813.
5. Lindh M, Johansson G, Hedberg M, Henning GB, Grimby G. Muscle fiber characteristics, capillaries and enzymes in patients with fibromyalgia and controls. Scand J Rheumatol. 1995;24(1):34-37.
6. Pongratz DE, Späth M. Morphologic aspects of fibromyalgia. Z Rheumatol. 1998;57(suppl 2):47-51.
7. Sprott H, Salemi S, Gay RE, et al. Increased DNA fragmentation and ultrastructural changes in fibromyalgic muscle fibres. Ann Rheum Dis. 2004;63(3):245-251.
8. Yunus MB, Kalyan Raman UP, Masi AT, Aldag JC. Electron microscopic studies of muscle biopsy in primary fibromyalgia syndrome: a controlled and blinded study. J Rheumatol. 1989;16(1):97-101.
9. Bennett RM. Emerging concepts in the neurobiology of chronic pain: evidence of abnormal sensory processing in fibromyalgia. Mayo Clin Proc. 1999;74(4):385-398.
10. Yunus MB. Towards a model of pathophysiology of fibromyalgia: aberrant central pain mechanisms with peripheral modulation. J Rheumatol. 1992;19(6):846-850.
11. Woolf CJ. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med. 2004;140(6):441-451.
12. DeLander GE, Hopkins CJ. Interdependence of spinal adenosinergic, serotonergic and noradrenergic systems mediating antinociception. Neuropharmacology. 1987;26(12):1791-1794.
13. Dickenson AH. Spinal cord pharmacology of pain. Br J Anaesth. 1995;75(2):193-200.
14. Fields HL, Heinricher MM, Mason P. Neurotransmitters in nociceptive modulatory circuits. Annu Rev Neurosci. 1991;14:219-245.
15. Malmberg AB, Yaksh TL. Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science. 1992;257(5074):1276-1279.
16. Skilling SR, Smullin DH, Larson AA. Differential effects of C- and N-terminal substance P metabolites on the release of amino acid neurotransmitters from the spinal cord: potential role in nociception. J Neurosci. 1990;10(4):1309-1318.
17. Moldofsky H. Rheumatic pain modulation syndrome: the interrelationships between sleep, central nervous system serotonin, and pain. Adv Neurol. 1982;33:51-57.
18. Fuller RW. The involvement of serotonin in regulation of pituitary-adrenocortical function. Front Neuroendocrinol. 1992;13(3):250-270.
19. Moldofsky H. Sleep and musculoskeletal pain. Am J Med. 1986;81(3A):85-89.
20. Houvenagel E, Forzy G, Leloire O, et al. Cerebrospinal fluid monoamines in primary fibromyalgia [French]. Rev Rhum Mal Osteoartic. 1990;57(1):21-3.
21. Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum. 1992;35(5):550-556.
22. Legangneux E, Mora JJ, Spreux-Varoquaux O, et al. Cerebrospinal fluid biogenic amine metabolites, plasma-rich platelet serotonin and [3H]imipramine reuptake in the primary fibromyalgia syndrome. Rheumatology (Oxford). 2001;40(3):290-296.
23. Russell IJ, Vipraio GA, Lopez YM. Serum serotonin in fibromyalgia syndrome, rheumatoid arthritis, osteoarthritis, and healthy normal controls [abstract]. Arthritis Rheum. 1993;36(9):S223.
24. Ernberg M, Voog U, Alstergren P, Lundeberg T, Kopp S. Plasma and serum serotonin levels and their relationship to orofacial pain and anxiety in fibromyalgia. J Orofac Pain. 2000;14(1):37-46.
25. Hrycaj P, Stratz T, Müller W. Platelet 3H-imipramine uptake receptor density and serum serotonin in patients with fibromyalgia/fibrositis syndrome. J Rheumatol. 1993;20(11):1986-1988.
26. Offenbaecher M, Bondy B, de Jonge S, et al. Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. Arthritis Rheum. 1999;42(11):2482-2488.
27. Murphy RM, Zemlan FP. Differential effects of substance P on serotonin-modulated spinal nociceptive reflexes. Psychopharmacology (Berl). 1987;93(1):118-121.
28. Vaeroy H, Helle R, Forre O, Kass E, Terenius L. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain. 1988;32(1):21-26.
29. Russell IJ, Orr MD, Liftman B, et al. Elevated Cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum. 1994;37(11):1593-1601.
30. Welin M, Bragee B, Nyberg F, et al. Elevated substance P levels are contrasted by a decrease inmetenkephalin-ARG-PHE levels in CSF from fibromyalgia patients. J Musculoskel Pain. 1995;3(suppl):4.
31. Bradley LA, Alberts KR, Alarcon GS. Abnormal brain regional cerebral blood flow (rCBF) and cerebrospinal fluid (CSF) levels of substance P (SP) in patients and non-patients with fibromyalgia (FM) [abstract]. Arthritis Rheum. 1996;39(suppl):212.
32. Russell IJ. Advances in fibromyalgia: possible role for central neurochemicals. Am J Med Sci. 1998;315(6):377-384.
33. Almay BG, Johansson F, Von Knorring L, Le Greves P, Terenius L. Substance P in CSF of patients with chronic pain syndromes. Pain. 1988;33(1):3-9.
34. Fischer HP, Eich W, Russell IJ. A possible role for saliva as a diagnostic fluid in patients with chronic pain. Semin Arthritis Rheum. 1998;27(6):348-359.
35. Sjostrom S, Tamsen A, Hartvig P, Folkesson R, Terenius L. Cerebrospinal fluid concentrations of substance P and (met)enkephalin-Arg6-Phe7 during surgery and patient-controlled analgesia. Anesth Analg. 1988;67(10):976-981.
36. Tsigos C, Diemel LT, White A, Tomlinson DR, Young RJ. Cerebrospinal fluid levels of substance P and calcitonin-gene-related peptide: correlation with sural nerve levels and neuropathic signs in sensory diabetic polyneuropathy. Clin Sci (Lond). 1993;84(3):305-311.
37. Schwarz MJ, Spath M, Müller-Bardorff H, Pongratz DE, Bondy B, Ackenheil M. Relationship of substance P, 5-hydroxyindole acetic acid and tryptophan in serum of fibromyalgia patients. Neurosci Lett. 1999;259(3):196-198.
38. Giovengo SL, Russell IJ, Larson M. Increased concentrations of nerve growth factor in Cerebrospinal fluid of patients with fibromyalgia. J Rheumatol. 1999;26(7):1564-1569.
39. Eide PK. Wind-up and the NMDA receptor complex from a clinical perspective. Eur J Pain. 2000;4(1):5-15.
40. Herrero JF, Laird JM, Lopez-Garcia JA. Wind-up of spinal cord neurones and pain sensation: much ado about something? Prog Neurobiol. 2000;61(2):169-203.
41. Woolf CJ. Evidence for a central component of post-injury pain hypersensitivity. Nature. 1983;306(5944):686-688.
42. Coderre TJ, Katz J, Vaccarino AL, Melzack R. Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. Pain. 1993;52(3):259-285.
43. Davies SN, Lodge D. Evidence for involvement of N-methylaspartate receptors in 'wind-up' of class 2 neurones in the dorsal horn of the rat. Brain Res. 1987;424(2):402-406.
44. Dougherty PM, Palecek J, Paleckova V, Sorkin LS, Willis WD. The role of NMDA and non-NMDA excitatory amino acid receptors in the excitation of primate spinothalamic tract neurons by mechanical, chemical, thermal, and electrical stimuli. J Neurosci. 1992;12(8):3025-3041.
45. Dougherty PM, Palecek J, Zorn S, Willis WD. Combined application of excitatory amino acids and substance P produces long-lasting changes in responses of primate spinothalamic tract neurons. Brain Res Brain Res Rev. 1993;18(2):227-246.
46. Dougherty PM, Willis WD. Enhancement of spinothalamic neuron responses to chemical and mechanical stimuli following-combined micro-iontophoretic application of N-methyl-D-aspartic acid and substance P. Pain. 1991;47(1):85-93.
47. Larson AA, Giovengo SL, Russell IJ, Michalek JE. Changes in the concentrations of amino acids in the Cerebrospinal fluid that correlate with pain in patients with fibromyalgia: implications for nitric oxide pathways. Pain. 2000;87(2):201-211.
48. Kranzler JD, Gendreau JF, Rao SG. The psychopharmacology of fibromyalgia: a drug development perspective. Psychopharmacol Bull. 2002;36(1):165-213.
49. Urban MO, Coutinho SV, Gebhart GF. Involvement of excitatory amino acid receptors and nitric oxide in the rostral ventromedial medulla in modulating secondary hyperalgesia produced by mustard oil. Pain. 1999;81(1-2):45-55.
50. Urban MO, Zahn PK, Gebhart GF. Descending facilitatory influences from the rostral medial medulla mediate secondary, but not primary hyperalgesia in the rat. Neuroscience. 1999;90(2):349-352.
51. Kovelowski CJ, Ossipov MH, Sun H, et al. Supraspinal cholecystokinin may drive tonic descending facilitation mechanisms to maintain neuropathic pain in the rat. Pain. 2000;87(3):265-273.
52. Jasmin L, Boudah A, Ohara PT. Long-term effects of decreased noradrenergic central nervous system innervation on pain behavior and opioid antinociception. J Comp Neurol. 2003;460(1):38-55.
53. Basbaum AI, Fields HL. Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Annu Rev Neurosci. 1984;7:309-338.
54. Mense S. Nociception from skeletal muscle in relation to clinical muscle pain. Pain. 1993;54(3):241-289.
55. Mense S. Neurobiological concepts of fibromyalgia - the possible role of descending spinal tracts. Scand J Rheumatol Suppl. 2000;113:24-29.
56. Crofford LJ, Engleberg NC, Demitrack MA. Neurohormonal perturbations in fibromyalgia. Baillieres Clin Rheumatol. 1996;10(2):365-378.
57. Crofford LJ, Pillemer SR, Kalogeras KT, et al. Hypothalamic-pituitary- adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum. 1994;37(11):1583-1592.
58. Crofford LJ, Young EA, Engleberg NC, et al. Basal circadian and pulsatile ACTH and cortisol secretion in patients with fibromyalgia and/or chronic fatigue syndrome. Brain Behav Immun. 2004;18(4):314-325.
59. Neeck G, Crofford LJ. Neuroendocrine perturbations in fibromyalgia and chronic fatigue syndrome. Rheum Dis Clin North Am. 2000;26(4):989-1002.
60. Heim C, Ehlert U, Hellhammer DH. The potential role of hypocortisolism in the pathophysiology of stress-related bodily disorders. Psychoneuroendocrinology. 2000;25(1):1-35.
61. Torpy DJ, Papanicolaou DA, Lotsikas AJ, et al. Responses of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis to interleukin-6: a pilot study in fibromyalgia. Arthritis Rheum. 2000;43(4):872-880.
62. Fuller RW. Serotonin receptors involved in regulation of pituitary-adrenocortical function in rats. Behav Brain Res. 1996;73(1-2):215- 219.